NCT00924911View on ClinicalTrials.gov

Relative Bioavailability Study in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

April 27, 2009

Primary Completion Date

July 9, 2009

Study Completion Date

July 9, 2009

Conditions

Infections, Bacterial

Interventions

DRUG

GSK1322322

Four different formulations of 1000mg of GSK1322322

DRUG

GSK1322322

GSK1322322 1000mg

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY